The objective of this trial is to evaluate the safety and effectiveness of Targeted Lung Denervation (TLD) for COPD patients using the lung denervation radiofrequency ablation device.
Participants aged ≥40 and ≤ 75 years;
Diagnosis of COPD with post-bronchodilator PFT parameters FEV1/FVC<70% and 20% ≤ FEV1 ≤ 60% of predicted; if FEV1<30%pred, PaCO2≤50mmHg;
CAT ≥ 10 or mMRC ≥2;
Non-smoking for a minimum of 2 months prior to consent and agrees to not smoke for the duration of the clinical investigation;
BMI < 18 or > 35;
Asthma as defined by the GINA guideline (2022);
Patient has been previously diagnosed with a non-COPD active lung disease (e.g., active tuberculosis);
Patient has a medical history of pneumothorax;